Filgotinib(Jyseleca)

Filgotinib is a prescription drug targeting Janus kinase 1 (JAK1). It was first approved for marketing in the European Union and Japan in September 2020. It should be used strictly under medical supervision.

Target of Action

Janus kinase 1 (JAK1)

Dosage and Administration

Route and frequency of administration for filgotinib: Oral, once daily.

The dosage of filgotinib should be adjusted according to the patient's actual condition. For specific adjustments, consult a physician and follow medical advice.

Recommended reading: Dosage and Administration of Filgotinib

Side Effects

Common side effects: Nausea, upper respiratory tract infections, etc.

Serious side effects: Serious infections (e.g., pneumonia), herpes zoster, etc.

Reference article: Side Effects of Filgotinib

Use in Special Populations

Pregnancy: Filgotinib is contraindicated in pregnant patients.

Lactation: It is unknown whether this drug is excreted into human milk. Breastfeeding women should not use filgotinib.

Daily Precautions

1. Before treatment, a comprehensive evaluation by a specialist is mandatory, with strict screening for contraindications and close monitoring during therapy.

2. Filgotinib is primarily metabolized by the CES2 enzyme. Caution is required when co-administered with CES2 inhibitors (e.g., simvastatin).

3. During treatment and for a period before and after, live vaccines are prohibited.

from FDA，2023.07